Product
Emtricitabine
5 clinical trials
7 indications
Indication
HIVIndication
HIV InfectionsIndication
HIV-1Indication
HIV/AIDSIndication
MenopauseIndication
Vaginal InflammationClinical trial
A Phase 3b, Multi-center, Randomized, Parallel-group, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Oral Dolutegravir/Lamivudine Once-daily as a First-line Regimen Compared to Oral Bictegravir/Emtricitabine/Tenofovir Alafenamide Once Daily for Virologic Suppression and Maintenance in Antiretroviral Therapy Naive Adults Living With HIVStatus: Not yet recruiting, Estimated PCD: 2025-09-22
Clinical trial
A Phase II, Open Label, Single Arm Trial to Evaluate the Pharmacokinetics,Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral Naive HIV-1 Infected Adolescents and Children Aged >= 6 to <18 YearsStatus: Completed, Estimated PCD: 2022-08-16
Clinical trial
An Open-Label, 48-Week Extension Study of Elvucitabine Administered In Combination With Background Antiretroviral Agents in Participants Who Have Completed 14 Days of Treatment in Protocol ACH443-014A.Status: Completed, Estimated PCD: 2008-12-01
Clinical trial
Quantification of Estradiol's Impact on Nucleotides in Different Cellular Populations of the Lower Gastrointestinal TractStatus: Completed, Estimated PCD: 2019-09-04
Clinical trial
Role of Exogenous and Endogenous Sex Hormones on Tenofovir and EmtricitabineStatus: Completed, Estimated PCD: 2024-02-15